Business Context and Reporting Period
This Form 8-K Current Report was filed by IDEAYA Biosciences, Inc. on December 18, 2019, regarding events occurring on December 17, 2019. The Company is a Delaware corporation incorporated as an emerging growth company, with its principal executive offices located in South San Francisco, California. Its common stock trades on The Nasdaq Global Select Market under the symbol "IDYA."
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change disclosed is the expansion of the Board of Directors. The Board size was increased from seven to eight members with the appointment of Wendy L. Yarno as a Class II independent director, effective December 17, 2019. Her initial term is set to expire at the 2021 annual meeting of stockholders.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or management commentary regarding business operations in this filing. The report details the compensatory arrangements for the new director, which include an option to purchase 22,000 shares of common stock. The exercise price is the closing price on December 17, 2019, with a vesting schedule of 1/36th of the shares on each monthly anniversary of the appointment, contingent on continued service. The Company also entered into a standard indemnification agreement with Ms. Yarno.
Important Facts for Investors to Verify
- Confirmation of Wendy L. Yarno's appointment as an independent director and her assignment to the Compensation Committee.
- The specific exercise price of the 22,000 share stock option granted to Ms. Yarno, based on the December 17, 2019 closing price.
- The full text of the press release issued on December 18, 2019, filed as Exhibit 99.1.
- Verification that no other undisclosed transactions or arrangements exist involving Ms. Yarno under Item 404(a) of Regulation S-K.